Treatment with Tavneos (avacopan) results in significant and clinically meaningful improvements in health-related quality of life (HRQoL) for people…
Articles by Margarida Maia, PhD
Dosing has begun in a Phase 2 clinical trial of imlifidase, an  antibody-cleaving therapy, in people with ANCA-associated vasculitis…
Developing pulmonary hypertension (PH), which occurs when pressure in the blood vessels that supply the lungs becomes too high,…
Nearly half of eosinophilic granulomatosis with polyangiitis (EGPA) patients are able to stop taking glucocorticoids after a median of nine…
Immunosuppressants may help prevent subglottic stenosis — a condition wherein part of the windpipe becomes tight — from returning in…
A blood marker, called C-reactive protein to albumin ratio (CAR), may predict and help monitor disease activity in people with…
Two types of self-reactive antibodies, called anti-HMGB1 and anti-moesin antibodies, are present at significantly higher levels in the blood of…
About 1 in 10 people with ANCA-associated vasculitis (AAV) failed to achieve complete remission at three months after starting…
Argenx is planning to launch a proof-of-concept clinical trial later this year to test its therapy efgartigimod, approved to…
May is Vasculitis Awareness Month and this year there are plenty of ways to get involved and raise awareness…